Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Mitchall G. Clark sold 3,021 shares of the stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $14.33, for a total transaction of $43,290.93. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Atara Biotherapeutics, Inc. (ATRA) traded down 2.20% during mid-day trading on Friday, hitting $13.35. 176,322 shares of the stock were exchanged. The stock’s 50 day moving average is $14.97 and its 200-day moving average is $15.91. Atara Biotherapeutics, Inc. has a 12 month low of $11.80 and a 12 month high of $23.40. The stock’s market cap is $407.96 million.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.05. On average, analysts anticipate that Atara Biotherapeutics, Inc. will post ($3.96) EPS for the current year.
Several brokerages recently commented on ATRA. Canaccord Genuity set a $47.00 price objective on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research report on Monday, August 7th. ValuEngine downgraded shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Jefferies Group LLC reissued a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, June 22nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. Three analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $25.75.
A number of large investors have recently modified their holdings of ATRA. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Atara Biotherapeutics during the first quarter worth approximately $132,000. Voya Investment Management LLC raised its stake in shares of Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after buying an additional 1,651 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Atara Biotherapeutics during the first quarter worth approximately $185,000. State of Wisconsin Investment Board purchased a new stake in shares of Atara Biotherapeutics during the second quarter worth approximately $252,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after buying an additional 1,369 shares in the last quarter. Hedge funds and other institutional investors own 78.21% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
